Jeff Cazeault joins FHI Clinical as Vice President, Business Development

November 5, 2019

FHI Clinical is pleased to announce that Jeff Cazeault has joined the company as Vice President, Business Development. In his new role, Jeff oversees the business development team and expansion of the FHI Clinical sales pipeline and portfolio by applying his background in global team development and management, strategic partnerships and sales strategy.

Jeff has provided disruptive growth and development in pharmaceutical, biotech, clinical research, healthcare tech, CI/market research and innovative healthcare start-up for more than 20 years. With experience in governance committees, joint business development and operational leadership structures, Jeff is an effective communicator and presenter to all levels of healthcare management and executive leadership.

“Jeff comes to us with a proven track record of driving growth in pharmaceutical, biotech, CRO, device and innovative early stage companies,” says Ted Fitzgerald, CEO. “His therapeutic experience in virology, immunology, pain and rare disease, makes him a fantastic addition to our FHI Clinical team.”

Most recently, Cazeault worked as a business development consultant serving biotech clients that included healthcare firms focusing on orphan and rare diseases and healthcare areas of unmet need. Prior to that, he was Vice President at Atlantic Research Group and his past experience also includes serving as Head of Global Sales at ELI Global Healthcare and various leadership roles at Bristol Myers Squibb Immunology and Boehringer Ingelheim Pharmaceuticals.  Cazeault also has extensive experience in the China pharmaceutical market in working with biotech companies in licensing and business development strategy.

Please join us in welcoming Jeff to FHI Clinical!

news archive

Evaluation of baricitinib versus dexamethasone for adults hospitalized with COVID-19 in the global ACTT-4 study

September 7, 2022
The global ACTT-4 study, supported by FHI Clinical, evaluated baricitinib vs dexamethasone for adults hospitalized with COVID-19. This trial is the fourth and final stage in a series of phase 3, randomized, double-blind, placebo-controlled trials to evaluate the clinical efficacy and safety of investigational therapeutic agents in hospitalized adults with laboratory-confirmed COVID-19.

Read more »

FHI Clinical announces the closing of its acquisition of the clinical trials business of South Africa-based Triclinium Clinical Development (TCD)

February 8, 2022
FHI Clinical Inc. announces today the official closing of its acquisition of the clinical trials business of Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South Africa-based CRO. With the acquisition, FHI Clinical expands its share of the infectious disease (ID) clinical development market and becomes the dominant service provider in sub-Saharan Africa.

Read more »

Share this post